PT - JOURNAL ARTICLE AU - Ward, Doyle V. AU - Bhattarai, Shakti AU - Rojas-Correa, Mayra AU - Purkayastha, Ayan AU - Holler, Devon AU - Da Qu, Ming AU - Mitchell, William G. AU - Yang, Jason AU - Fountain, Samuel AU - Zeamer, Abigail AU - Forconi, Catherine AU - Fujimori, Gavin AU - Odwar, Boaz AU - Cawley, Caitlin AU - McCormick, Beth A. AU - Moormann, Ann AU - Wessolossky, Mireya AU - Bucci, Vanni AU - Maldonado-Contreras, Ana TI - THE INTESTINAL AND ORAL MICROBIOMES ARE ROBUST PREDICTORS OF COVID-19 SEVERITY THE MAIN PREDICTOR OF COVID-19-RELATED FATALITY AID - 10.1101/2021.01.05.20249061 DP - 2021 Jan 01 TA - medRxiv PG - 2021.01.05.20249061 4099 - http://medrxiv.org/content/early/2021/01/06/2021.01.05.20249061.short 4100 - http://medrxiv.org/content/early/2021/01/06/2021.01.05.20249061.full AB - The reason for the striking differences in clinical outcomes of SARS-CoV-2 infected patients is still poorly understood. While most recover, a subset of people become critically ill and succumb to the disease. Thus, identification of biomarkers that can predict the clinical outcomes of COVID-19 disease is key to help prioritize patients needing urgent treatment. Given that an unbalanced gut microbiome is a reflection of poor health, we aim to identify indicator species that could predict COVID-19 disease clinical outcomes. Here, for the first time and with the largest COVID-19 patient cohort reported for microbiome studies, we demonstrated that the intestinal and oral microbiome make-up predicts respectively with 92% and 84% accuracy (Area Under the Curve or AUC) severe COVID-19 respiratory symptoms that lead to death. The accuracy of the microbiome prediction of COVID-19 severity was found to be far superior to that from training similar models using information from comorbidities often adopted to triage patients in the clinic (77% AUC). Additionally, by combining symptoms, comorbidities, and the intestinal microbiota the model reached the highest AUC at 96%. Remarkably the model training on the stool microbiome found enrichment of Enterococcus faecalis, a known pathobiont, as the top predictor of COVID-19 disease severity. Enterococcus faecalis is already easily cultivable in clinical laboratories, as such we urge the medical community to include this bacterium as a robust predictor of COVID-19 severity when assessing risk stratification of patients in the clinic.Competing Interest StatementBeth A. McCormick (BMC) is a Scientific Founder of the start-up company Bacainn Therapeutics. The remaining authors do not have any conflict of interest to disclose.Funding StatementThe Center for Microbiome Center, AM, GF, CF received funding to execute this study by the COVID-19/Pandemic Research Fund at UMass Medical School. Funding sources for AM, GF, CF were also provided by MassCPR Evergrande AwardAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board at the University of Massachusetts Medical School approved this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll sequencing data will be available upon submission.